KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Operating Leases (2019 - 2025)

NovoCure (NVCR) has disclosed Operating Leases for 7 consecutive years, with $41.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 108.54% to $41.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.6 million through Dec 2025, up 108.54% year-over-year, with the annual reading at $41.6 million for FY2025, 108.54% up from the prior year.
  • Operating Leases hit $41.6 million in Q4 2025 for NovoCure, down from $42.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $42.9 million in Q2 2025 to a low of $11.5 million in Q3 2021.
  • Historically, Operating Leases has averaged $22.8 million across 5 years, with a median of $20.2 million in 2023.
  • Biggest five-year swings in Operating Leases: decreased 27.17% in 2024 and later soared 108.54% in 2025.
  • Year by year, Operating Leases stood at $13.0 million in 2021, then surged by 44.36% to $18.8 million in 2022, then skyrocketed by 46.15% to $27.4 million in 2023, then fell by 27.17% to $20.0 million in 2024, then skyrocketed by 108.54% to $41.6 million in 2025.
  • Business Quant data shows Operating Leases for NVCR at $41.6 million in Q4 2025, $42.7 million in Q3 2025, and $42.9 million in Q2 2025.